Series “A” round of CHF 25 million

Digital optical information on the outcome of breast cancer. Come with the selling party in contact via Brookz

OMZET

€ 50.000.000

EBITDA

€ 15.000.000

AANTAL FTE

6-10

REGIO

Niet locatiegebonden

SECTOR

Gezondheidszorg & farmacie
IT, online & e-commerce

TYPE KLANTEN

B2B

PROFIELNUMMER

#30242

RECHTSVORM

B.V.

Beschrijving

The company is the first company to act with digital optical information on the outcome of a major disease, breast cancer. It shortens significantly and improves drastically the breast cancer treatment process by giving oncologists, with its proprietary non-invasive optical molecular digital data technology, critical in vivo tissue’s pathophysiological activity information to immediately select the most efficacious and individualized cancer treatment for a given patient. It thus avoids the successive invasive trials and potential inefficacy of 2 or 3 treatments over 2-3 months for each. It permits physicians to remotely monitor the progress of their treatments. In addition, it may in the future replace mammography with a much earlier, non-invasive and accurate diagnosis of breast cancer for a wider range of women, from teenage to senior years, in private physician offices or at home.

Reason to sell
The entrepreneur wants to attract a strategic partner.

Suitable for
The company is interesting for strategic buyers/investors. The company is interesting as well for entreprenerial MBI candidates who have knowledge of the sector. 

Offerd stake
The offered stake is to be discussed.

Transaction form
To be discussed.

Asking price
The asking price is € 25.000.000.

Opleiding uitgelicht

RSM business valuation

Dé opleiding in Nederland voor waarderingsdeskundigen met ambitie! Neem deel aan de online informatiesessie op vrijdag 25 juni en leer meer over het Business Valuation programma.